Characteristics and prognostic factors among premenopausal versus postmenopausal patients with advanced endometrial cancer: a SEER-based analysis

The aim of this study was to assess risk factors associated with developing second cancer in premenopausal and postmenopausal endometrial cancer survivors using data from the Surveillance, Epidemiology, and End Results (SEER) database. Multivariate analysis revealed that for both groups age was a risk factor for second cancer development. For premenopausal women, being white versus black, having endometrioid adenocarcinoma compared with other histological types increased the risk of developing a second cancer (p values ≤ 0.018). For postmenopausal women, being Non-Spanish-Hispanic-Latino versus Spanish-Hispanic-Latino, having squamous cell carcinoma versus endometroid adenocarcinoma, N0 compared with N1 nodes, M0 versus M1 metastasis, and no surgery or radiotherapy compared with surgery alone or surgery plus radiotherapy increased the likelihood of developing second cancer (p values ≤ 0.012). The results of Cox proportional hazard analysis indicated that premenopausal and postmenopausal women with endometrial cancer who underwent surgery plus radiotherapy showed the greatest benefit with respect to cause-specific survival (adjusted HR 0.192, 95%CI: 0.135 to 0.274, and adjusted HR 0.206, 95%CI, 0.184 to 0.230, respectively). In summary, risk factors for second cancer in survivors of endometrial cancer differ between premenopausal and postmenopausal women, and suggests that the two groups of women should be managed differently.

Endometrial cancer; Premenopausal; Postmenopausal; Second primary cancer; Prognosis; Surveillance Epidemiology and End Results (SEER) Program.

[1] World Health Organization, International Agency for Research on Cancer: GLOBOCAN 2012: Estimated cancer incidence, mortality, and prevalence worldwide in 2012. Population fact sheets”. 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.

[2] Baden L.R., Bensinger W., Angarone M., Casper C., Dubberke E.R., Freifeld A.G., et al.: “National Comprehensive Cancer Network clinical practice guidelines in oncology: Prevention and treatment of cancer related infections, version 1.2012 2012”. Available at: http://www.nccn.org/professionals/physician_gls/pdf/infections.pdf.

[3] American Cancer Society: “Endometrial (uterine) cancer: detailed guide”. Available at: http://www.cancer.org/cancer/endometrialcancer/detailedguide/endometrial-cancer-detailed-guide-toc.

[4] “Uterine cancer treatment—health professional version (PDQ)”. Available at: https://www.cancer.gov/types/uterine/hp/endometrial-treatmentpdq.

[5] Zeng X.Z., Lavoue V., Lau S., Press J.Z., Abitbol J., Gotlieb R., How J., et al.: “Outcome of robotic surgery for endometrial cancer as a function of patient age”. Int. J. Gynecol. Cancer, 2015, 25, 637.

[6] Amant F., Moerman P., Neven P., Timmerman D., Van Limbergen E., Vergote I.: “Endometrial cancer”. Lancet, 2005, 366, 491.

[7] Nevadunsky N.S., Van Arsdale A., Strickler H.D., Moadel A., Kaur G., Levitt J., et al.: “Obesity and age at diagnosis of endometrial cancer”. Obstet. Gynecol., 2014, 124, 300.

[8] Plataniotis G., Castiglione M., Group E.G.W.: “Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Ann. Oncol., 2010, 21, v41.

[9] Beavis A.L., Smith A.J., Fader A.N.: “Lifestyle changes and the risk of developing endometrial and ovarian cancers: opportunities for prevention and management”. Int. J. Womens Health, 2016, 8, 151.

[10] Morice P., Leary A., Creutzberg C., Abu-Rustum N., Darai E.: “Endometrial cancer”. Lancet, 2016, 387, 1094.

[11] Wiltink L.M., Nout R.A., Fiocco M., Meershoek-Klein Kranenbarg E., Jürgenliemk-Schulz I.M., Jobsen J.J., et al.: “No Increased Risk of Second Cancer After Radiotherapy in Patients Treated for Rectal or Endometrial Cancer in the Randomized TME, PORTEC-1, and PORTEC-2 Trials”. J. Clin. Oncol., 2015, 33, 1640.

[12] Berrington de Gonzalez A., Curtis R.E., Kry S.F., Gilbert E., Lamart S., Berg C.D., et al.: “Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries”. Lancet Oncol., 2011, 12, 353.

[13] Herrera F.G., Cruz O.S., Achtari C., Bourhis J., Ozsahin M.: “Longterm outcome and late side effects in endometrial cancer patients treated with surgery and postoperative radiation therapy”. Ann. Surg. Oncol., 2014, 21, 2390.

[14] Martin-Dunlap T.M., Wachtel M.S., Margenthaler J.A.: “Outcomes for patients who are diagnosed with breast and endometrial cancer”. Oncol. Lett., 2013, 6, 1103.

[15] Mell L.K., Carmona R., Gulaya S., Lu T., Wu J., Saenz C.C., Vaida F.: “Cause-specific effects of radiotherapy and lymphadenectomy in stage I-II endometrial cancer: a population-based study”. J. Natl. Cancer Inst., 2013, 105, 1656.

[16] Zwahlen D.R., Ruben J.D., Jones P., Gagliardi F., Millar J.L., Schneider U.: “Effect of intensity-modulated pelvic radiotherapy on second cancer risk in the postoperative treatment of endometrial and cervical cancer”. Int. J. Radiat. Oncol. Biol. Phys., 2009, 74, 539.

[17] de Boer S.M., Nout R.A., Jürgenliemk-Schulz I.M., Jobsen J.J., Lutgens L.C., van der Steen-Banasik E.M., et al.: “Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial”. Int. J. Radiat. Oncol. Biol. Phys., 2015, 93, 797.

[18] Onsrud M., Cvancarova M., Hellebust T.P., Tropé C.G., Kristensen G.B., Lindemann K.: “Long-term outcomes after pelvic radiation for early-stage endometrial cancer”. J. Clin. Oncol., 2013, 31, 3951.

[19] Brown A.P., Neeley E.S., Werner T., Soisson A.P., Burt R.W., Gaffney D.K.: “A population-based study of subsequent primary malignancies after endometrial cancer: genetic, environmental, and treatment-related associations”. Int. J. Radiat. Oncol. Biol. Phys., 2010, 78, 127.

[20] Kumar S., Shah J.P., Bryant C.S., Awonuga A.O., Imudia A.N., Ruterbusch J.J., et al.: “Second neoplasms in survivors of endometrial cancer: impact of radiation therapy”. Gynecol. Oncol., 2009, 113, 233.